Royalty Pharma PLC (RPRX) — 8-K Filings

All 8-K filings from Royalty Pharma PLC. Browse 28 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (28)

8-K Filing — Apr 13, 2026
Royalty Pharma plc Files 8-K for Regulation FD Disclosure — Dec 22, 2025 Risk: low
Royalty Pharma plc announced a Regulation FD Disclosure on December 19, 2025. The filing, submitted on December 22, 2025, pertains to information that may be ma
Royalty Pharma plc Files 8-K: Material Agreement & Financials — Sep 16, 2025 Risk: medium
On September 16, 2025, Royalty Pharma plc entered into a material definitive agreement. The filing also indicates other events and the submission of financial s
Royalty Pharma plc Files 8-K on Executive Changes — Aug 13, 2025 Risk: low
Royalty Pharma plc filed an 8-K on August 13, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of c
Royalty Pharma plc Files 8-K on Financials — Aug 6, 2025 Risk: low
On August 6, 2025, Royalty Pharma plc filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as
Royalty Pharma plc Files 8-K on Executive Changes and Financials — Jul 17, 2025 Risk: low
Royalty Pharma plc filed an 8-K on July 17, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of cer
Royalty Pharma plc Files 8-K: Agreements, Acquisitions, and Executive Changes — May 19, 2025 Risk: medium
On May 16, 2025, Royalty Pharma plc entered into a material definitive agreement related to the creation of a direct financial obligation. The company also comp
Royalty Pharma plc Files 8-K on Security Holder Vote — May 12, 2025 Risk: low
On May 12, 2025, Royalty Pharma plc filed an 8-K report indicating a submission of matters to a vote of security holders. The filing does not contain specific d
Royalty Pharma plc Files 8-K for Operations Update — May 8, 2025 Risk: low
Royalty Pharma plc filed an 8-K on May 8, 2025, reporting on its Results of Operations and Financial Condition, and filing Financial Statements and Exhibits. Th
Royalty Pharma plc Files 8-K — Apr 11, 2025 Risk: medium
On April 11, 2025, Royalty Pharma plc entered into a material definitive agreement. The filing does not provide specific details about the agreement, its counte
Royalty Pharma PLC Reports Director Changes and Compensation Updates — Apr 10, 2025 Risk: low
Royalty Pharma plc announced on April 7, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the depa
Royalty Pharma plc Files 8-K for Financial Reporting — Feb 11, 2025 Risk: low
Royalty Pharma plc filed an 8-K on February 11, 2025, to report on its results of operations and financial condition, as well as to file financial statements an
Royalty Pharma plc Files Form 8-K — Jan 13, 2025 Risk: low
On January 13, 2025, Royalty Pharma plc (RPRX) filed a Form 8-K to report its current status. The filing confirms the company's principal executive offices are
Royalty Pharma plc Files 8-K for Financial Reporting — Jan 10, 2025 Risk: low
Royalty Pharma plc filed an 8-K on January 10, 2025, to report on its results of operations and financial condition, as well as to file financial statements and
Royalty Pharma plc (RPRX) Files 8-K — Jan 10, 2025 Risk: low
On January 10, 2025, Royalty Pharma plc (RPRX) filed an 8-K report. The filing confirms the company's principal executive offices are located at 110 East 59th S
Royalty Pharma Files 8-K on Material Agreements — Dec 31, 2024 Risk: low
Royalty Pharma plc filed an 8-K on December 31, 2024, reporting on a material definitive agreement, amendments to its articles of incorporation or bylaws, and f
Royalty Pharma Files 8-K on Financials — Nov 6, 2024 Risk: low
Royalty Pharma plc filed an 8-K on November 6, 2024, to report on its results of operations and financial condition, as well as to file financial statements and
Royalty Pharma Buys Pfizer Royalty for $2.25B — Sep 27, 2024 Risk: medium
Royalty Pharma plc announced on September 26, 2024, that it has entered into a definitive agreement to acquire a royalty interest in certain products from Pfize
Royalty Pharma plc Files 8-K on Financials — Aug 8, 2024 Risk: low
Royalty Pharma plc filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibi
Royalty Pharma plc Files 8-K Report — Aug 7, 2024 Risk: low
On August 6, 2024, Royalty Pharma plc filed an 8-K report to disclose information under Regulation FD. The filing confirms the company's principal executive off
Royalty Pharma Buys J&J Tremfya Royalties for $500M — Jun 20, 2024 Risk: medium
On June 17, 2024, Royalty Pharma plc announced the closing of its acquisition of a portion of the future royalty rights on Tremfya (guselkumab) from Johnson & J
Royalty Pharma plc Files 8-K: Material Agreement & Financial Obligations — Jun 10, 2024 Risk: medium
On June 10, 2024, Royalty Pharma plc entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or a
Royalty Pharma plc Files 8-K on Security Holder Votes — Jun 6, 2024 Risk: low
Royalty Pharma plc filed an 8-K on June 6, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain details about the
Royalty Pharma plc Files 8-K for Material Definitive Agreement — Jun 4, 2024 Risk: medium
On June 3, 2024, Royalty Pharma plc entered into a material definitive agreement. The company, headquartered at 110 East 59th Street, New York, NY, filed an 8-K
Royalty Pharma plc Files 8-K Report — May 29, 2024 Risk: low
On May 29, 2024, Royalty Pharma plc filed an 8-K report. The filing primarily serves as a notification of other events, with no specific material transactions o
Royalty Pharma plc Files 8-K on Financials — May 9, 2024 Risk: low
Royalty Pharma plc filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exh
Royalty Pharma Files 8-K for 'Other Event' on Feb 5, 2024 — Feb 6, 2024
Royalty Pharma plc filed an 8-K on February 6, 2024, reporting an "Other Event" that occurred on February 5, 2024. This filing, under Item 8.01, indicates a rou
Royalty Pharma Files 8-K on Financial Results, Exhibits — Jan 8, 2024
Royalty Pharma plc filed an 8-K on January 8, 2024, to report on its 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits.' Th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX